

## IX GEMCAD SYMPOSIUM

Valencia, March 30<sup>th</sup> & 31<sup>st</sup>, 2023

Palacio de las Artes Reina Sofía

### Thursday, March 30th 2023

17:00 – 17:30 h

*Welcome coffee*

**17:30 - 19:00h**

#### **SESSION I: Adenocarcinoma of the Esophagus and Gastroesophageal Junction (GEJ)**

17:30 - 17:50h

Quality of care requirements in the multidisciplinary management of gastroesophageal cancer.

17:50 - 18:10h

Are we facing a new gold standard for treatment of MSI tumors?

18:10 - 18:30h

Gastric sporadic cancer in young adults. A new entity?

18:30 - 19:00h

Discussion

**19:00 - 20:00 h**

#### **GEMCAD GENERAL ASSEMBLY**

### Friday, March 31st 2023

**08:00 - 09:00 h**

**Working group meetings**

**09:00 - 10:00 h**

**Industry Meeting**

**10:00 - 11:30 h**

#### **SESSION II: Pancreatic, biliary and hepatic cancer**

10:00 - 10:20h

Role of fecal microbiota in early diagnosis of pancreatic cancer

10:20 - 10:40h

Systemic therapy in hepatocellular carcinoma: do recent trials change clinical practice?

10:40 - 11:00h

SBRT in the management of cholangiocarcinoma

11:00 - 11:30h

Discussion

|                        |  |
|------------------------|--|
| <b>11:30 - 12:00</b>   | <b>Coffee</b>  |
| <b>12:00 - 13:30h</b>  | <b>SESSION III: Colorectal cancer</b>  |
| 12:00 - 12:20h         | Short-term neoadjuvant vs long-term adjuvant immune checkpoint blockade therapy for resectable MSI colon cancer  |
| 12:20 - 12:40h         | Metabolism and immune suppression in advanced microsatellite stable colorectal cancer  |
| 12:40 - 13:00h         | Role of chemotherapy doublets and triplets plus targeted agents in patients with initially unresectable colorectal liver metastases                        |
| 13:00 - 13:30h         | Discussion   |
| <b>13:30 - 14:30h</b>  | <b>Lunch</b>   |
| <b>14:30 - 16:00 h</b> | <b>SESSION IV: Rectal Cancer</b>   |
| 14:30 - 14:50h         | TNT and NOM. Ideal patient profile and practical considerations for implementation in centers. How to improve the assessment of clinical complete response |
| 14:50 - 15:10h         | Immunotherapy in the preoperative treatment of localized (MSS and MSI) rectal cancer Current data, ongoing studies, and strategies to improve results      |
| 15:10 - 15:30h         | Liquid biopsy in localized rectal cancer. Summary of results and future research strategies  |
| 15:30 - 16:00          | <b>Discussion</b>  |
| <b>16:00 - 16:10 h</b> | <b>Conclusions and closure</b>   |